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To study plasma arachidonic acid (AA) and docosahexaenoic acid (DHA) status in Tunisian very low birth weight
(VLBW) infants and their association with selected neonatal morbidities. A total of 709 VLBW infants and 339 term
infants were included. Plasma fatty acids were analyzed using capillary gas chromatography. VLBW infants had
significantly (p < 0.001) lower plasma AA (9.44 ± 2.12 vs. 10.8 ± 2.10) and DHA (2.56 ± 0.89 vs. 3.46 ± 1.09) levels, but
higher n-6:n-3 ratio (5.58 ± 1.22 vs. 5.17 ± 1.46) than term infants. In VLBW infants, plasma AA and DHA were related
to gestational age (r = 0.156; p = 0.001 and r = 0.134; p = 0.003, respectively), birthweight (r = 0.242; p < 0.001 and
r = 0.181; p < 0.001, respectively) and head circumference (r = 0.138; p = 0.005 and r = 0.108; p = 0.027, respectively).
Infants with respiratory distress syndrome have decreased plasma AA and DHA and those with intraventricular
hemorrhage have decreased plasma AA and n-6:n-3 ratio. Sepsis was associated with decreased DHA levels. Plasma
long chain polyunsaturated fatty acids status is low in VLBW infants. These deficits may enhance the risk of common
neonatal morbidities, rendering their prevention and correction greatly warranted.
Keywords: Arachidonic acid, Docosahexaenoic acid, Intraventricular hemorrhage, Sepsis, Preterm infants, Respiratory
distress syndrome, Small for gestational ageBackground
Long chain-polyunsaturated fatty acids (LCPUFAs) ara-
chidonic acid (AA, C20:4 n-6) and docosahexaenoic acid
(DHA, C22:6 n-3) are critical for neural, visual and
vascular development [1, 2]. The development and mat-
uration of the nervous system in Humans begins in
utero and extends over the two first years of life, period
during which the needs of the fetus and newborn in AA
and DHA are elevated [3, 4]. Fetal needs in these LC-
PUFAs are mainly covered by placenta transfer, which
substantially increases during the third trimester of preg-
nancy with little synthesized into fetus [1, 5]. Preterms
may be in disadvantage compared to term infants re-
garding PUFAs status due to a shortened gestation [4, 6]
and low activity of enzymes responsible of endogen
synthesis of LCPUFAs [7–9]. In addition to their role in* Correspondence: samirafares@yahoo.fr
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are essential modulators of immune function and in-
flammation. Their alteration during the postnatal period
in premature infants may results in a dysregulation of
immune and inflammatory responses, which may predis-
pose them to neonatal morbidities [10–12]. Thus, the
evaluation of PUFAs status at birth could be an import-
ant predictor for infants' development and health. The
present study was aimed to determine the AA and DHA
status and its determinants in VLBW infants and to test
their association with selected neonatal morbidities.
Methods
Subjects
The study included 736 preterm VLBW neonates (birth
weight <1500 g and gestational age <37 weeks) and 339
term healthy neonates (birth weight between 2500 and
3500 g) as controls. All neonates were born between
2005 and 2008 in The Center of Maternity and Neonat-
ology of Tunis. This Center is the most important publicicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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pregnant women of low to average socioeconomic rank.
Malformed neonates, those with chromosomal abnor-
mality were excluded. Infants with birth weight <650 g
or gestational age <27 weeks were not included as their
chances of survival are greatly reduced in our practice.
The study protocol was approved by the Ethics Commit-
tee of Maternity Center and informed consent was ob-
tained from each mother.
Maternal and infant characteristics
Relevant information was collected from medical records.
They included maternal age, medical and obstetrical his-
tory and the course of the current pregnancy. Almost all
mothers had prenatal care. The majority of them have
low fish intake (average once a month) and no one has
taken fish oil or vitamins supplements during the preg-
nancy. Preeclampsia and gestational diabetes are defined
according to American College of Obstetricians and
Gynecologists criteria [13, 14]. Infant's data included gen-
der, gestational age, birthweight and existence of small
for gestational age (SGA), as well as the occurrence
during the hospital stay of selected neonatal diseases
including respiratory distress syndrome (RDS), sepsis and
intraventricular hemorrhage (IVH). SGA is defined as a
weight below the 10th percentile for the gestational age
[15]. RDS was defined as respiratory distress with CXR
abnormality, requiring respiratory support in the form of
nasal continuous positive airway pressure or mechanical
ventilation or the administration of surfactant. Late-onset
sepsis was defined as the occurrence of at least one
episode of clinical symptoms of infection and a positive
result on 1 or more blood cultures obtained after 72 h of
life. Diagnosis of IVH was based on specific features in
serial transfontanellar ultrasound [16]. For reason of
information’s lack in some records, the association of
fatty acids with neonatal morbidities was studied in 480
preterm infants.
Collection of blood samples and preparation
Blood was collected following medical prescription for
cell count analysis in VLBW infants and for ABO Rhesus
grouping in term infants. Blood (1 to 2 ml) was drawn
between 8 and 10 a.m. by veinupuncture from neonates
within the first 24 h of life into EDTA containing tubes.
After completion of the prescribed analysis, the tube was
recovered (into 2 h) and centrifuged at 2500 g. Plasma
(300 μl) was added with 20 μL butylated hydroxytoluene
(25 mg in 100 ml ethanol) as antioxidant and stored at
−80 °C until analysis (within 6 months).
Analytical methods
Plasma fatty acids were analyzed by capillary gas chroma-
tography according to the method of Moser and Moser[17]. Plasma lipids were extracted by methylene chloride/
methanol mixture in presence of heptadecanoic acid as
internal standard and hydrolyzed by potassium carbon-
ate, and fatty acids were methylated in presence of acetyl
chloride. The resulting fatty acid methyl esters were
extracted by hexane and analyzed with a gas chromato-
graph model 6890 N (Agilent Technologies, Santa Clara,
CA), equipped with split/splitless capillary intel system
and flame ionization detector. Separation was achieved
on capillary column (Innowax; 30 m × 0.25 mm; ID,
0.25 mm; Agilent Technologies) using nitrogen as carrier
gas. The oven temperature was programmed from 150 °C
to 250 °C. The injector and detector temperatures were
230 and 280 °C, respectively. The fatty acids were identi-
fied by comparison of relative retention time with authen-
tic standards and results are expressed as percent of total
fatty acids weight (mol%).
Statistical analysis
Statistical analysis was performed using the SPSS version
15.0 software package (SPSS Inc., Chicago, USA). The
data of each continuous variable were examined for
normality using the Kolmogrov-Smiranov test. Conti-
nuous variables were compared between groups using
independent-samples T test. The relationship between
continuous variables was tested using Pearson r coeffi-
cient of correlation. In order to test how the association
between fatty acids and selected neonatal illnesses is
independent of confounding factors, multi linear regres-
sion models were performed with AA, DHA or n-6:n-3
ratio as response variable, and gestational age, birthweigt,
twin pregnancy, preeclampsia, gestational diabetes and
selected neonatal illness (SGA, RDS, sepsis or IVH) as
independent variables. Goodness-of-fit of logistic models
were satisfactory. A p value < 0.05 based on two-sided
calculation was considered significant.
Results
The main maternal and preterm infants’ characteristics
and neonatal outcomes are shown in Table 1. Compared
to term infants, VLBW infants showed significantly higher
plasma saturated fatty acids (SFAs) and monounsaturated
fatty acids (MUFAs), but lower PUFAs. Both plasma AA
and DHA were lower, and n-6:n-3 ratio was significantly
higher in VLBW compared to term infants. The differ-
ences remained significant when excluding infants whose
mothers have suffered from preeclampsia or gestational
diabetes (Table 2).
In VLBW infants, no gender differences were observed
for either individual fatty acids or n-6:n-3 ratio. Infants
issued from twin pregnancy have a significant lower
plasma DHA (2.44 ± 0.84 vs. 2.68 ± 0.92, p = 0.007) and
higher n-6:n-3 ratio (5.78 ± 1.17 vs. 5.45 ± 1.28; p = 0.009)
than singleton. Plasma AA and DHA, but not n-6:n-3
Table 1 Data of preterm infants and mothers
Preterm infants (n = 480)
Infant's characteristics
Gestational age, weeks
27–31 340 (70.8 %)
32–37 140 (29.2 %)
Birthweight, g
650–999 107 (21.1 %)
1000–1499 373 (77.9 %)
Gender
Male 240 (50.0 %)
Female 240 (50.0 %)
Maternal and pregnancy characteristics
Twin pregnancy 149 (31.0 %)
Preeclampsia 214 (44.6 %)
Gestational diabetes 24 (5.0 %)
Cesarean section 338 (70.4 %)
Neonatal morbidities
Small for gestational age 142 (29.6 %)
Respiratory distress syndrome 234 (48.8 %)
Sepsis 218 (45.4 %)
Intaventricular hemorrhage 86 (17.9 %)
Values represent number of cases (percent)
Table 2 Plasma fatty acid profile (mol%) at birth in term and
preterm infants
Term infants Preterm infants
(n = 339) All (n = 709) Without GD or PE
in mothers (n = 482)
Palmitic acid (C16:0) 30.0 (2.56) 30.5 (2.25)** 30.6 (2.29)**
Stearic acid (C18:0) 10.0 (1.62) 10.7 (1.54)*** 10.7 (1.53)***
Oleic acid (C18:1 n-9) 24.8 (2.57) 27.2 (2.11)*** 27.3 (2.01)***
Linoleic acid (C18:2 n-6) 10.7 (1.99) 9.37 (2.14)*** 9.27 (2.14)***
Alpha Linolenic acid
(C18:3 n-3)
0.39 (0.17) 0.31 (0.12)*** 0.30 (0.12)***
Arachidonic acid
(C20:4 n-6)
10.8 (2.10) 9.44 (2.12)*** 9.35 (2.09)***
Eicosapentaenoic acid
(C20:5 n-3)
0.54 (0.32) 0.52 (0.30)** 0.48 (0.30)**
Docosahexaenoic acid
(C22:6 n-3)
3.46 (1.09) 2.56 (0.89)*** 2.55 (0.88)***
Saturated fatty acids
(SFAs)
41.2 (3.29) 42.7 (3.20)*** 42.8 (3.25)***
Monounsaturated fatty
acids (MUFAs)
29.9 (2.90) 32.7 (2.56)*** 32.8 (2.47)***
Polyunsaturated fatty
acids (PUFAs)
28.8 (4.39) 24.7 (5.01)*** 24.5 (4.96)***
Essential fatty acids (EFAs) 11.1 (2.03) 9.71 (2.24)*** 9.61 (2.24)***
n-6:n-3 PUFAs 5.17 (1.46) 5.58 (1.22)*** 5.51 (1.16)***
GD gestational diabetes, PE preeclampsia; SFAs = C14:0 + C16:0 + C18:0; MUFAs =
C16:1 n-7 + C18:1 n-9; EFAs = C18:2 n-6 + C18:3 n-3; PUFAs = n-6 PUFAs (C18:2
n-6 + C18:3 n-6 + C20:3 n-6 + C20:4 n-6) + n-3 PUFAs (C18:3 n-3 + C22:5 n-3 +
C22:6 n-3)
Values represent mean (SD); **, p < 0.01, ***, p < 0.001 (compared to term
infants)
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0.001 for AA and r = 0.134, p = 0.003 for DHA), birth-
weight (r = 0.242, p < 0.001 for AA and r = 0.181, p <
0.001 for DHA) (Fig. 1), and head circumference (r =
0.138, p = 0.005 for AA and r = 0.108, p = 0.027 for
DHA).
No differences were observed for plasma AA, DHA
levels and n-6:n-3 ratio according to SGA. In univariate
analysis, VLBW infants who developed sepsis had lower
plasma DHA levels and those with RDS have signifi-
cantly lower plasma AA levels. Infants with IVH had
lower AA levels and n-6:n-3 ratio. In multi linear regres-
sion models, AA was related to birthweight, DHA was
related to birthweight, twin pregnancy and RDS, and n-
6:n-3 ratio was related to twin pregnancy and IVH
(Table 3).
Discussion
This study showed lower plasma AA and DHA levels in
Tunisian VLBW neonates compared to term infants. In
VLBW neonates, AA and DHA levels were associated
with the degree of prematurity; the lower the gestational
age and the birthweight the lower AA and DHA levels.
The delivery of PUFAs substantially increases during
the third trimester, coinciding with continued organ de-
velopment and rapid fetal growth [5, 17]. Fatty acid pla-
cental transfer is characterized by the biomagnificationphenomenon, consisting in preferential placental deliv-
ery of DHA and AA to the fetus [18]. Preterm delivery
interrupts placental supply of these critical fatty acids
and prevents the effect of biomagnification. The early
termination of selective fatty acid delivery, coupled with
a feeble LCPUFAs synthesis from fatty acid precursors
and a lack of adipose tissue stores in immature tissues
[3, 9] may explain the low DHA and AA status in VLBW
infants. During neonatal life, PUFA needs are greater in
preterm infant who requires more nutrients to ensure
maturation and development of its tissues and organs.
However, the nutritional management strategies usually
fail to meet the LCPUFA fetal accretion requirements
and thus may contribute to further decline of these fatty
acids during the first postnatal period [18–20]. As a con-
sequence, preterm infants are disadvantaged with respect
to access to AA and DHA needed for brain maturation
compared with term infants. These deficits would expose
VLBW infants to a higher risk for neonatal morbidities
[20]. Gestational diabetes and preeclampsia are known
to limit placental transfer of PUFAs. These conditions
are very common in our series and would have contrib-
uted to the altered fatty acids profile in VLBW infants.
Fig. 1 Correlations of plasma arachidonic acid and docosahexaenoic acid with gestational age and birthweight (n = 480)
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infants issued from pregnancies with these conditions
were excluded.
The study showed that plasma AA and DHA levels are
lower in VLBW neonates who will develop RDS or sepsis.
These fatty acids and their derivatives have ability to
modulate immune function and inflammatory responses.
Their alteration during the postnatal period in premature
infants may contribute to a dysregulation of immune and
inflammatory responses, which may predispose them to
neonatal morbidities. DHA-derived metabolites such as
resolvins decrease neutrophil infiltration and enhance
macrophage phagocytosis [21]. DHA also down regulatesTable 3 Plasma arachidonic acid (AA) and docosahexaenoic acid (D
to selected neonatal morbidities (n = 480)
Small for gestational age No 338
Yes 142




Intraventricular hemorrhage No 394
Yes 86
Values are expressed as mean (SD); *, p < 0.05; **, p <0.01; ***, p < 0.001 (univariate
birthweight, twin pregnancy, preeclampsia and gestational diabetes)nuclear factor κB (NF-κB) activity in cells either directly
or via increased activation of peroxisome proliferator
activated receptors (PPARs), thereby reducing cytokine
release [22, 23]. Lastly, DHA competes with AA for
incorporation into cell membranes thus limiting the pro-
inflammatory signaling mediated by AA [21, 23]. There-
fore, low levels of DHA would be expected to predispose
to increased host inflammatory responses such as that
seen in sepsis. In RDS, decreased AA levels may increase
the risk by inhibiting the innate immune response through
decreased eicosanoids, in particular, leukotrienes, which
are known to enhance chemotaxis of leukocytes, neutro-
phil activation, and activity of natural killer cells [22].HA) levels (in mol%) and n-6:n-3 ratio in VLBW infants according
AA (mol%) DHA (mol%) n-6:n-3 ratio
9.46 (2.10) 2.61 (0.87) 5.53 (1.20)
9.48 (2.30) 2.60 (0.99) 5.60 (1.38)
9.71 (2.19) 2.74 (0.95) 5.66 (1.21)
9.22 (2.09)** 2.47 (0.91)***,**** 5.44 (1.28)*
9.60 (2.13) 2.69 (0.94) 5.52 (1.31)
9.32 (2.18) 2.51 (0.85)* 5.59 (1.20)
9.55 (2.11) 2.62 (0.93) 5.62 (1.27)
9.01 (2.20)* 2.56 (0.82) 5.27 (1.22)*,****
analysis); ****, p < 0.05 (multivariate analysis, adjusting for gestational age,
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associated with a greater risk for IVH. This bleeding into
the microvascular tissue lining the brain ventricles in-
volves factors that affect cerebral vascular tone and flux,
angiogenesis, inflammation and coagulation [24]. Reduced
AA levels could lead to leaking cell membranes and
impair the balance of vasodilator and vasoconstrictor and
pro- and antithrombotic eicosanoids produced by the
endothelium and platelets [1, 25].
The n-6:n-3 ratio has functional consequences in
addition to individual fatty acids in influencing disease
[26, 27]. This ratio regulates inflammatory mediators and
other downstream modulators of cell and organ physi-
ology [26–28]. Our data showed that n-6:n-3 ratio is
decreased in infants with IVH. This decrease is due to low
rates of n-6 PUFAs, mainly LA and AA. Previous studies
have showed that a better control of the n-6:n-3 balance
may represent an interesting target in the prevention and/
or control of a large number of neonatal morbidities in
premature infants, such as sepsis and chronic diseases.
Conclusion
In total, LCPUFAs, mainly AA and DHA are low in
VLBW Tunisian neonates. Such decrease is related to
lack in transplacental transfer and reduced activity of
enzymes responsible for endogen synthesis from essen-
tial fatty acids. Altered fatty acid levels may favor the
development of common neonatal morbidities such as
RDS, sepsis and IVH in these neonates. Therefore,
efforts should be undertaken to enhance the PUFAs
status in preterm infants. The strategy would include an
increase of LCPUFAs intake in pregnant and breastfeed-
ing women and feeding neonates with LCPUFAs-rich
formula or LCPUFAs-fortified breast milk. Tight control
of recurrent infections, preeclampsia and gestational
diabetes in pregnant women may fight against premature
birth and then prevent LCPUFAs deficits in neonates.
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